Cell-scaffold constructs
The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.
1. A urinary diversion for a defective bladder in a subject comprising
a) a first implantable, biocompatible construct comprising a tubular scaffold having a first end configured to form a stoma and connect to an abdominal wall section, a second closed end, and at least a first side opening configured to connect to a first ureter; and
b) an autologous cell population that is not derived from the defective bladder, deposited on or in a surface of the scaffold,
wherein the urinary diversion is adapted to provide passage of urine out of the subject.
2. The urinary diversion of claim 1 wherein the scaffold further comprises a second side opening configured to connect to a second ureter.
3. The urinary diversion of claim 1 wherein the first end is configured to be positioned flush with the abdominal wall.
4. The urinary diversion of claim 3 wherein the first end is configured to be sutured to the skin of the subject.
5. The urinary diversion of claim 1 wherein the stoma further comprises a stoma button.
6. The urinary diversion of claim 1 , wherein the biocompatible scaffold is biodegradable.
7. The urinary diversion of claim 1 , wherein the scaffold comprises a material selected from the group consisting of polyglycolic acid, polylactic acid, and a copolymer of polyglycolic acid and polylactic acid.
8. The urinary diversion of claim 1 , wherein the cell population is a smooth muscle cell population.
9. The urinary diversion of claim 1 , wherein the diversion is free of urothelial cells.
10. The urinary diversion of claim 8 , wherein the smooth muscle cell population is derived from adipose.
11. The urinary diversion of claim 8 , wherein the smooth muscle cell population is derived from peripheral blood.
12. The urinary diversion of any one of claims 8 , 10 , and 11 , wherein the SMC population is not derived from in vitro differentiation of mesenchymal stem cells (MSCs).
13. The urinary diversion of claim 1 , wherein the first end is an open end configured for anastomosis to an opening in the subject's abdominal wall.
14. The urinary diversion of claim 1 , wherein the first end is an open end configured to be anastomosed to the skin.
15. The urinary diversion of claim 1 , wherein the tubular scaffold is coated with a biocompatible and biodegradable shape-setting material.
16. The urinary diversion of claim 15 , wherein the shape-setting material comprises a poly-lactide-co-glycolide copolymer.